1. Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan

   • Imad Treish
   • Abeer Al Rabayah
   • Haitham Tuffaha

   Practical Application Open access 13 November 2021 Pages: 137 - 145

2. Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review

   • Ana-Catarina Pinho-Gomes
   • John Cairns

   Review Article Open access 20 August 2021 Pages: 147 - 167

3. Budget Impact of the Vest™ High Frequency Chest Wall Oscillation System for Managing Airway Clearance in Patients with Complex Neurological Disorders: A US Healthcare Payers’ Perspective Analysis

   • Amir Ansaripour
   • Kari Roehrich
   • Mehdi Javanbakht

   Original Research Article Open access 01 September 2021 Pages: 169 - 178

   

4. Cost Effectiveness of Internet-Delivered Acceptance and Commitment Therapy for Patients with Severe Health Anxiety: A Randomised Controlled Trial

   • Bettina Wulff Risør
   • Ditte Hoffmann Frydendal
   • Lisbeth Frostholm

   Original Research Article Open access 08 January 2022 Pages: 179 - 192

   

5. Examining Ways to Improve Weight Control Programs’ Population Reach and Representativeness: A Discrete Choice Experiment of Financial Incentives

   • Wen You
   • Yuan Yuan
   • Paul A. Estabrooks

   Original Research Article Open access 10 November 2021 Pages: 193 - 210

   

6. Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study

   • Pedro Labisa
   • Valeska Andreozzi
   • Igor Beitia Ortiz de Zarate

   Original Research Article Open access 03 October 2021 Pages: 211 - 218

   

7. Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016–2018

   • Rose J. Geurten
   • Jeroen N. Struijs
   • Dirk Ruwaard

   Original Research Article Open access 04 December 2021 Pages: 219 - 229

   

8. Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States

   • Siu Hing Lo
   • Andrew Lloyd
   • Floortje E. van Nooten

   Original Research Article Open access 17 September 2021 Pages: 231 - 239

9. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective

   • Will Dunlop
   • Marjolijn van Keep
   • Alastair Greystoke

   Original Research Article Open access 16 September 2021 Pages: 241 - 252

   

10. Budget Impact Analysis of an Epigenetic Test Used for Diagnosing Fetal Alcohol Spectrum Disorder from the Perspective of a Laboratory Budget Holder in Manitoba, Canada

    • Patrick Berrigan
    • Geoffrey G. Hicks
    • Jennifer D. Zwicker

    Original Research Article Open access 10 October 2021 Pages: 253 - 263

    

11. The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation

    • Ahmed H. Seddik
    • Nima Melzer
    • Dennis A. Ostwald

    Original Research Article Open access 19 October 2021 Pages: 265 - 275

    

12. Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia

    • Ahmed Alghamdi
    • Bander Balkhi
    • Rima Aziziyeh

    Original Research Article Open access 28 September 2021 Pages: 277 - 291

    

13. Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium

    • B. Gillain
    • G. Degraeve
    • I. Vandersmissen

    Original Research Article Open access 15 November 2021 Pages: 293 - 302

    

14. Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide

    • Dikshyanta Rana
    • Claudia Geue
    • Olivia Wu

    Original Research Article Open access 10 November 2021 Pages: 303 - 313